Amgen (AMGN.US) hires Duke Clinical Research Institute for independent re-evaluation to ensure the flagship drug Tavneos is not delisted.

Zhtng Cijng APP hu xl, zi Migu shpn yofng jinggun gunl j (FDA) y shj cozng h nqun xng wnt wi yu ty jing rnjin bng yow Tavneos ch ch shchng hu, n jn (AMGN.US) y pnq Dk lngh shyn su (Duke Clinical Research Institute) du gunjin lngh shj jnxng dl chngxn pnggu, sht wi zh kun ninxioshu yu 5 y miyun de chnpn zhngq zhun j.